Catalent (NYSE:CTLT) Announces Earnings Results, Misses Expectations By $0.18 EPS

Catalent (NYSE:CTLT) released its quarterly earnings results on Tuesday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18), Briefing.com reports. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the prior year, the business earned ($0.10) earnings per share. The company’s revenue for the quarter was up 4.2% on a year-over-year basis.

Catalent Trading Up 2.4 %

NYSE:CTLT traded up $1.41 during mid-day trading on Wednesday, hitting $59.89. The company had a trading volume of 2,784,774 shares, compared to its average volume of 2,042,626. The firm has a market cap of $10.87 billion, a P/E ratio of -10.65, a P/E/G ratio of 2.06 and a beta of 1.16. Catalent has a fifty-two week low of $32.38 and a fifty-two week high of $61.20. The business’s fifty day moving average is $60.03 and its two-hundred day moving average is $58.02. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a report on Thursday, July 11th. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. StockNews.com initiated coverage on Catalent in a report on Saturday, October 12th. They set a “hold” rating on the stock. William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. Nine analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $59.83.

Insider Buying and Selling

In other Catalent news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.31% of the stock is owned by insiders.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.